Replies to post #10302 on Biotech Values

[DewDiligence]

>>I'm glad to see it going forward, but there is still no indication as to what the outstanding issues are.<<

Today’s PR lowers the probability of having to run new clinical trials, IMO. I previously said that probability was 25%, but the tenor of today’s PR allows me to lower that to 10% at most.